{"id":"aripiprazole-long-acting-injectable-formulation","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Akathisia"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Anxiety"},{"rate":"5-10","effect":"Insomnia"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Weight gain"},{"rate":"5","effect":"Tremor"},{"rate":"5-10","effect":"Injection site pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole acts as a partial agonist at dopamine D2 and D3 receptors, providing stabilization of dopaminergic signaling in the brain. Unlike typical antipsychotics that block dopamine, its partial agonist activity allows it to reduce dopamine activity when it is excessive (in psychosis) while maintaining activity when dopamine is deficient. The long-acting injectable formulation provides sustained therapeutic levels over weeks to months, improving medication adherence.","oneSentence":"Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat psychotic and mood disorders.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:35.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute agitation and maintenance)"},{"name":"Major depressive disorder (adjunctive treatment)"},{"name":"Irritability associated with autism spectrum disorder"}]},"trialDetails":[{"nctId":"NCT05662306","phase":"PHASE4","title":"C-Cog in Early Course Schizophrenia Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2024-01-23","conditions":"Schizophrenia","enrollment":1},{"nctId":"NCT02360319","phase":"PHASE4","title":"Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics","status":"COMPLETED","sponsor":"Vanguard Research Group","startDate":"2014-12-11","conditions":"Schizophrenia","enrollment":489},{"nctId":"NCT02146547","phase":"PHASE4","title":"European Long-acting Antipsychotics in Schizophrenia Trial","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2015-02","conditions":"Schizophrenia","enrollment":536},{"nctId":"NCT02087579","phase":"PHASE1","title":"Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":305}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"aripiprazole long acting injectable formulation","genericName":"aripiprazole long acting injectable formulation","companyName":"Vanguard Research Group","companyId":"vanguard-research-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole long-acting injectable formulation is a small molecule that acts as a partial agonist at the dopamine D2 receptor. It is used to treat conditions such as schizophrenia, psychotic disorders, bipolar disorder, and depressive disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}